P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Updates on Isatuximab in Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
Philippe Moreau,Katja Weisel +1 more
TL;DR: In the past decade, therapies that are more effective and less toxic have transformed the treatment landscape for patients with MM, but many patients will eventually become refractory to the current haematologic standard of care treatments of proteasome inhibitors, immunomodulatory agents, and mAb therapies.
Journal ArticleDOI
Results from a Meta-Analysis of Ciltacabtagene Autoleucel Compared to Physician’s Choice in Patients with Relapsed or Refractory Multiple Myeloma
Parameswaran Hari,Jesus G. Berdeja,Valerio De Stefano,F. Gay,B. Hooper,Anja Haltner,Shaji Kumar,Thomas Martin,Maria-Victoria Mateos,Philippe Moreau,Emily Rosta,Imtiaz A. Samjoo,Saad Z. Usmani,Katja Weisel,Carolyn C. Jackson,Yunsi Olyslager,Jordan M. Schecter,Martin Vogel,A. Garrett,Sam Lee,Tonia Nesheiwat,Lida Bubuteishvili Pacaud,Changwei Zhou,Satish Valluri,Luciano J. Costa,Yi Lin +25 more
Journal ArticleDOI
P958: real-life current standard of care in patients with relapsed/refractory multiple myeloma: subgroup analyses from the locommotion study
Hermann Einsele,Philippe Moreau,Virgilio De Stefano,Dominik Dytfeld,Emanuele Angelucci,R. Benjamin,Hartmut Goldschmidt,N. W. van de Donk,Britta Besemer,Christof Scheid,Rashmi Vij,E. I. ’. Groen-Damen,M. Semerjian,Vadim Strulev,J. Schecter,Tito Roccia,Tonia Nesheiwat,Robert Wapenaar,Katja Weisel,M.V. Mateos +19 more
Journal ArticleDOI
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
Binod Dhakal,Kwee Yong,Simon J. Harrison,Maria-Victoria Mateos,Philippe Moreau,N. W. C. J. van de Donk,Surbhi Sidana,Rakesh Popat,Nikoletta Lendvai,Carolina Lonardi,Ana R. Slaughter,Jordan M. Schecter,Katherine Li,Enrique Zudaire,Ying Chen,Jane S. Gilbert,Lida Bubuteishvili-Pacaud,Jesús F. San Miguel,Hermann Einsele +18 more
TL;DR: CARTITUDE-4 as discussed by the authors is a global, phase 3, randomized, controlled trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel), a dual-binding, BCMA-targeting CAR-T cell therapy, vs standard of care (SOC), in lenalidomide (len)-refractory patients (pts).
Journal ArticleDOI
OAB-039: Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study
Philippe Moreau,Thierry Facon,Saad Z. Usmani,Shaji Kumar,Torben Plesner,Hartmut Goldschmidt,Robert Z. Orlowski,Aurore Perrot,Ajai Chari,Gordon Cook,Huiling Pei,Rian Van Rampelbergh,J. Blake Bartlett,Clarissa M. Uhlar,Robin Carson,Nizar J. Bahlis +15 more